Tech Company Financing Transactions

Replimune Funding Round

On 9/11/2017, Replimune raised $55 million in Series B investment from Foresite Capital, Atlas Venture and Bain Capital Life Sciences.

Transaction Overview

Company Name
Announced On
9/11/2017
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series B
Proceeds Purpose
These funds will also enable us to establish in house GMP manufacturing capabilities in preparation for the later stage clinical development and commercialization of our products.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Unicorn Park Dr. 3rd Floor
Woburn, MA 01801
USA
Email Address
Overview
Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response.
Profile
Replimune LinkedIn Company Profile
Social Media
Replimune Company Twitter Account
Company News
Replimune News
Facebook
Replimune on Facebook
YouTube
Replimune on YouTube

Management Team

Title
Name
Email & Social
Chairman
Philip Sparke
  Philip Sparke LinkedIn Profile  Philip Sparke Twitter Account  Philip Sparke News  Philip Sparke on Facebook
Chief Executive Officer
Robert Coffin
  Robert Coffin LinkedIn Profile  Robert Coffin Twitter Account  Robert Coffin News  Robert Coffin on Facebook
Chief Operating Officer
Colin Love
  Colin Love LinkedIn Profile  Colin Love Twitter Account  Colin Love News  Colin Love on Facebook
VP - Bus. Development
Pamela Esposito
  Pamela Esposito LinkedIn Profile  Pamela Esposito Twitter Account  Pamela Esposito News  Pamela Esposito on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/11/2017: Petal venture capital transaction
Next: 9/12/2017: Pegasus Solar venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to document every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary